← Human Trials & Peer-Reviewed Studies
Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism
Plain-language guide to PMID 20861820 (2011): randomized controlled trial study of Parathyroid Hormone (PTH 1-84) in 60 patients, hyperparathyroidism.
Key Facts
- PMID
- 20861820
- Journal
- Kidney international
- Year
- 2011
- Study type
- Randomized Controlled Trial
- Authors
- Wesseling-Perry K et al. (8 authors)
- DOI
- 10.1038/ki.2010.352
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Parathyroid Hormone (PTH 1-84) in the context of hyperparathyroidism.
The researchers compared the effects of calcitriol and doxercalciferol, in combination with either calcium carbonate or sevelamer, on bone, mineral, and fibroblast growth factor-23 (FGF-23) metabolism in patients with secondary hyperparathyroidism.
On initial bone biopsy, a mineralization defect was identified in the majority of patients which did not normalize with therapy.
Who Took Part
The study group was 60 patients.
The age groups tagged for this paper are teenagers, both men and women.
A total of 60 pediatric patients treated with peritoneal dialysis were randomized to 8 months of therapy with either oral calcitriol or doxercalciferol, combined with either calcium carbonate or sevelamer.
How the Study Was Run
The researchers set it up as a randomized study.
The patients were allocated by chance, so the Parathyroid Hormone (PTH 1-84) group and the comparison group should start out alike.
What Was Measured
The researchers compared the effects of calcitriol and doxercalciferol, in combination with either calcium carbonate or sevelamer, on bone, mineral, and fibroblast growth factor-23 (FGF-23) metabolism in patients with secondary hyperparathyroidism.
PubMed files the paper under topics including Bone Density Conservation Agents, Bone and Bones, Calcitriol, Calcium Carbonate, Chronic Kidney Disease-Mineral and Bone Disorder, Ergocalciferols and Fibroblast Growth Factor-23.
What This Means in Plain Language
The paper is a randomized study of Parathyroid Hormone (PTH 1-84) in 60 patients in people with hyperparathyroidism.
The publication is from 2011 (Kidney international), a journal based in United States.
More context: the Parathyroid Hormone (PTH 1-84) compound page, Hyperparathyroidism research.
Our Notes on the Compound
Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.